{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"groups":[{"description":"PHASE I: Patients receive flavopiridol IV over 4½ hours on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of flavopiridol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.\n\nPHASE II: Patients receive flavopiridol\\* as in phase I at the MTD determined in phase I.\n\nalvocidib: Given IV","id":"OG000","title":"All Dose Levels of Alvocidib"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 30 days after completion of study treatment","title":"Number of Patients Reporting Acute Infusion Toxicity (e.g., Fever, Hypotension, Tumor Pain, and Dyspnea)","type":"SECONDARY","unitOfMeasure":"patients"}